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number of symptoms (3) was associated with a higher
viral load. Lower viral load at initial surveillance testing
correlated with an increased likelihood of being asymp-
tomatic initially and remaining asymptomatic throughout
the viral shedding episode. These results provide initial
support for the use of viral load as a clinical endpoint in
interventional trials.460
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Background: Tacrolimus is extensively employed in allo-
geneic hematopoietic cell transplant (alloHCT) for the
prevention of graft-versus-host disease (GvHD). Renal and
hepatic toxicities have been associated with increased
blood concentrations post alloHCT. Due to the narrow
therapeutic index of tacrolimus and variability in blood
concentrations, drug monitoring is essential. Difﬁculties
of therapeutic monitoring include dosage forms limitedFigure A. Depletion of DNMT1 in HCT116-WT and DKO cells cultured with 0.5mM de
ﬂow cytometry in a patient with relapsed AML post-transplant who was treated with p
at T+32 after reduced-intensity allo-HCT and before starting parenteral azacitidine (40
after start of azacitidine. The DNMT1 level was determined in CD34+CD117+ and S-pto capsules, drug interactions, and changes in organ
function.
Methods: All patients were initiated on 0.005 mg/kg (ideal
body weight) intravenously every 12 hours on Day -1
through a central venous catheter. Tacrolimus trough levels
were drawn twice weekly by peripheral vein (Tuesday and
Fridays). Once levels were stable in the therapeutic range (5
to 15 ng/mlddesired target between 5 to 10 ng/ml), doses
were converted to the solution formulation of 1 mg/ml
(Elefante et al BBMT 2006). Datawere collected from January
2013 to March 2014.
Results: Eighty-seven patients were admitted for alloHCT
during this time period. Of these 87 patients, 527 tacrolimus
adjustments were performed. These adjustments resulted in
12 out of greater than 10,000 levels drawn to be outside the
upper recommended range of 15 ng/ml.
Conclusions: Tacrolimus adjustments utilizing the intrave-
nous and solution dosage forms allowed doses to be adjusted
in smaller increments minimizing the frequency of toxic
trough levels.461
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Disease relapse is a major cause of treatment failure
following alloSCT for acute myeloid leukemia (AML). Azaci-
tidine has shown efﬁcacy in treating, and preventing, post-
transplant relapse in patients with AML. Post-SCT azacitidine
administration is challenging due to the possibility of mye-
losuppression and an incomplete understanding of the
optimal dose and schedule. DNMT1 is responsible for
genome methylation in S phase and degraded after bonding
irreversibly to substituted DNA. Hence, the DNMT1 level may
be an attractive pharmacodynamic (PD) endpoint for azaci-
tidine therapy.
We developed a novel DNMT1 assay by ﬂow cytometry as a
PD endpoint for hypomethylating agent therapy. To validate
the assay, HCT116-wild type (WT) and DNMT1-double-
knockout (DKO) cells were incubatedwith 0.5 mMdecitabine,
and were harvested, ﬁxed, and processed for ﬂow cytometry
using DNMT1 antibody in an indirect assay and co-stained
with DAPI to measure DNA content. We assessed the time-
dependent depletion of DNMT1 with decitabine incubation
(Fig. A).
We subsequently assessed DNMT1 in ﬁxed peripheral
blood leukocytes using the same method in 4 AML patients
treated with post-alloSCT azacitidine; either parenterally for
post-SCT relapse (n¼2) or after oral azacitidine maintenance
on clinical protocol NCT 01835587 (n¼2). Peripheral blood
samples were drawn before and 2-6 weeks after starting
azacitidine. Immature myeloblasts were identiﬁed by co-
staining for CD34 and CD117.
We demonstrated depletion in DNMT1 in S-phase
CD34+CD117+ cells after azacitidine in the 4 studied paired
samples. The degree of depletionwas more pronounced with
parenteral versus oral azacitidine. In one patient who
responded favorably to azacitidine, depletion of DNMT1
correlated with reduction in peripheral blood blasts
(CD34+117+ cells) as shown below (Fig. B).
These preliminary data suggest that the DNMT1 assay is a
robust single cell approach to assess PD of hypomethylating
agents. After further validation, this DNMT1 assay may be a
valuable tool to optimize the dose and schedule, and hence
the safety and efﬁcacy of post-alloSCT hypomethylating
therapies.Figure 1. FLT image reconstruction axial spine462
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There are no tests that diagnose graft failure early after he-
matopoietic stem cell transplantation (HSCT); currently, bi-
opsies of single sites are used, thereby limited by small
volume of HSCs. To enhance evaluation of the entire marrow
space, we have developed a new methodology using an
imaging probe, 3’-deoxy-3 18F-ﬂuorothymidine (18FLT) PET/
CT. Previously, by drawing regions of interest on 18FLT PET-
CTs, uptake correlated with rate of engraftment after HSCT.
This approach is limited by subjective choice of regions
within bones. To enhance objectivity and sensitivity, we
developed a computer-based algorithm to isolate the entire
medullary space and determine standard uptake value
(SUV). This method was applied to images from 17 patients
